Lixte Biotechnology Holdings (LIXT) - שווי פעילות לרווח לפני ריבית, מסים ופחת
The market price action for Lixte Biotechnology (LIXT), a lean oncology pharma company featuring a flat management structure and an option system, as visualized on the GURU.Markets platform for analytical convenience, demonstrates the 0.00 indicator. The business focuses on developing protein phosphatase inhibitors, including the promising LB-100, while expanding its partnership with the NCI to combat tumor resistance. The company is currently actively conducting clinical trials for agents designed to enhance the efficacy of chemotherapy for solid tumors.
LIXT (lixte.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Lixte Biotechnology's development of antitumor drugs relies on scientific potential and patent protection, rendering the business resilient to macroeconomic cycles. The company's EV/EBITDA trajectory demonstrates the ratio of enterprise value to operating profit, allowing investors to assess the payback period for liabilities and determine the asset's fundamental margin of safety through the lens of capital intensity.
